SWP
RGNX icon

Stratos Wealth Partners’s Regenxbio RGNX Stock Holding History

Stratos Wealth Partners’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-225
Closed -$17K – 2132
2018
Q3 		$17K Buy
+225
New +$16.2K ﹤0.01% 1958
2018
Q2 		– Sell
-225
Closed -$7K – 2222
2018
Q1 		$7K Buy
+225
New +$6.55K ﹤0.01% 2486

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Stratos Wealth Partners's RGNX Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 225 shares — an estimated $17K sold.

Stratos Wealth Partners first reported a position in RGNX in Q1 2018 and held it in 2 quarters. The position peaked at $17K in Q3 2018. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 225 Regenxbio shares in Q4 2018, an estimated $17K.
  • Stratos Wealth Partners first reported a position in Regenxbio in Q1 2018 and held it in 2 quarters.
  • Stratos Wealth Partners's Regenxbio position peaked at $17K in Q3 2018.
  • 183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.